IVUS

Intravascular Ultrasound (IVUS) Global Strategic Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024

The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Medical Ultrasound, with a specific focus on Intravascular Ultrasound (IVUS) and its applications in the medical field.
  • It begins with a general introduction to medical ultrasound and highlights the advantages of ultrasound as compared to other imaging modalities.
  • The report discusses the indications and techniques of Intravascular Ultrasound, providing a comprehensive understanding of its use in medical procedures.

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

Retrieved on: 
Wednesday, January 3, 2024

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.
  • HeartFlow’s FFRCT provides clear insights into each patient’s condition with a patient-specific visual model of the heart’s blood flow.
  • Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease.
  • “We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMapTM Analysis.

Evident Vascular Announces Scientific Advisory Board and New Board Member

Retrieved on: 
Monday, October 30, 2023

Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.

Key Points: 
  • Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.
  • “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board.
  • “We are also pleased to welcome Bruce Shook to the Evident Vascular Board of Directors.
  • Evident Vascular is developing the first IVUS platform designed for peripheral interventions, with enhanced ease of use and improved image quality.

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
  • In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
  • The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

Evident Vascular Exits Stealth with $35 Million Series A Funding to Develop Intravascular Imaging Platform

Retrieved on: 
Tuesday, October 17, 2023

Evident Vascular, Inc. , a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today that it has launched with a $35 million Series A financing from Vensana Capital® .

Key Points: 
  • Evident Vascular, Inc. , a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today that it has launched with a $35 million Series A financing from Vensana Capital® .
  • “The impetus to launch Evident Vascular was born out of the Vensana team’s extensive experience in the vascular space.
  • Evident Vascular is addressing a critical need in the IVUS market, making it an ideal company to add to our vascular technology innovations.”
    IVUS is a transcatheter intravascular imaging technique used to acquire images from inside blood vessels to evaluate vascular disease and guide interventional treatment.
  • “Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications.

Magenta Medical Completes Enrollment to Early Feasibility Study for World's Smallest Heart Pump

Retrieved on: 
Tuesday, August 22, 2023

KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical, developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital. The Elevate™ Early Feasibility Study was approved by the FDA to evaluate the safety and feasibility of the Elevate™ System in providing temporary mechanical circulatory support during HR-PCI procedures, and constitutes the first step in a clinical program intended to secure approval for the device in the US for this indication.

Key Points: 
  • KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical , developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication.
  • All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital.
  • "Having now used the system in nine complex, high-risk PCI cases, I can truly appreciate its advantages," said Dr. Sharma.
  • The percutaneous Elevate™ heart pump is inserted over a guidewire through commercially available 10 Fr introducer sheaths that require a small puncture in the groin.

New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions

Retrieved on: 
Friday, July 28, 2023

MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.
  • HeartFlow is the first company to offer a suite of technologies to help clinicians non-invasively identify stenoses in the coronary arteries ( RoadMap™Analysis ), assess coronary blood flow ( FFR C T Analysis ), and characterize and quantify coronary atherosclerosis ( Plaque Analysis ).
  • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools, allowing clinicians to see the full picture of their patients’ coronary artery disease (CAD).
  • "Until now, clinicians have not had access to a complete view of a patient’s heart health with accurate data on coronary anatomy, physiology, and plaque.

Starlight Cardiovascular Appoints Paul G. Yock, MD to its Board of Directors

Retrieved on: 
Tuesday, June 13, 2023

SAN DIEGO, June 13, 2023 /PRNewswire/ -- Paul G. Yock has joined the Starlight Cardiovascular Board of Directors. Dr. Yock is the Founder, Director Emeritus, and a Board Member of the Stanford Byers Center for Biodesign. He is the former Martha Meier Weiland Professor of Medicine, founding co-chair of Stanford University's Department of Bioengineering, and the 2018 recipient of the National Academy of Engineering's Gordon Prize for Innovation in Engineering and Technology Education. Yock, who is trained as an interventional cardiologist, is known for his numerous innovative contributions to medical technology, including the Rapid Exchange angioplasty and stenting system, intravascular ultrasound (IVUS), and the Smart Needle.

Key Points: 
  • SAN DIEGO, June 13, 2023 /PRNewswire/ -- Paul G. Yock has joined the Starlight Cardiovascular Board of Directors.
  • "We are overjoyed that Paul has joined the Starlight family," stated Beverly Tang, co-Founder and CEO of Starlight Cardiovascular.
  • Yock was appointed as an independent director and joins Alf Grunwald, Tom Duerig, and Beverly Tang on the Board of Directors.
  • "Starlight Cardiovascular is taking on this challenge by developing highly novel pediatric technologies -- and, equally important, pioneering novel approaches to business execution.

REVOLUTIONIZING CARDIOLOGY: AI-BASED TECHNOLOGY OFFERS ACCURATE ANALYSIS OF CARDIAC DISEASE

Retrieved on: 
Monday, June 12, 2023

TORONTO, June 12, 2023 /PRNewswire/ -- New research published in JMIR Cardio reveals the remarkable potential of artificial intelligence (AI) technology in analyzing coronary angiography, a common diagnostic procedure for coronary artery disease. Led by Dr. In Tae Moon, the study conducted at Uijeongbu Eulji University Hospital in Korea showcases the power of AI-based quantitative coronary angiography (AI-QCA) in enhancing clinical decision-making.

Key Points: 
  • In Tae Moon , the study conducted at Uijeongbu Eulji University Hospital in Korea showcases the power of AI-based quantitative coronary angiography (AI-QCA) in enhancing clinical decision-making.
  • The analysis included 54 significant lesions from 47 patients who underwent IVUS-guided coronary intervention.
  • AI-QCA offers an innovative approach to analyze coronary angiography images, providing automated and real-time insights.
  • While the study provides promising results, further research is required to fully explore the clinical utility and safety of AI-QCA.